Category Archives: Psoriasis

Psoriasis Treatment Marketresearch report is the new statistical data source added byA2Z Market Research.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Psoriasis Treatment Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280493

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO Pharma A/S, Eli Lilly and Company, UCB S.A., Johnson and Johnson Services, Inc., CELGENE CORPORATION, Pfizer Inc.,, AbbVie Inc., Merck and Co., Inc..

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=280493

Global Psoriasis Treatment Market Segmentation:

Market Segmentation: By Type

TNF InhibitorsInterleukinsOthers

Market Segmentation: By Application

Hospital PharmaciesRetail PharmaciesOnline pharmacies

Regions Covered in the Global Psoriasis Treatment Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Psoriasis Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Psoriasis Treatment market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Psoriasis Treatment market.

Table of Contents

Global Psoriasis Treatment Market Research Report 2020 2026

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=280493

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the rest here:
Impact of COVID-19 on Psoriasis Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Sun Pharmaceutical Industries...

The Chronic Plaque Psoriasis Therapeutics Market grew in 2019, as compared to 2018, according to our report, Chronic Plaque Psoriasis Therapeutics Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Chronic Plaque Psoriasis Therapeutics Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Chronic Plaque Psoriasis Therapeutics Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-chronic-plaque-psoriasis-therapeutics-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Chronic Plaque Psoriasis Therapeutics Market is analysed based on product types, major applications and key players

Key product type:ClinicalNon-ClinicalInactive

Key applications:HospitalsAmbulatory Surgical CentersOthers

Key players or companies covered are:AbbvieNovartis InternationalPfizerMerckAstelllas PharmaGlaxoSmithKline

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-chronic-plaque-psoriasis-therapeutics-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Chronic Plaque Psoriasis Therapeutics Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Chronic Plaque Psoriasis Therapeutics Market?4. What is the likely market forecast & how will be Chronic Plaque Psoriasis Therapeutics Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Chronic Plaque Psoriasis Therapeutics Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Visit link:
Chronic Plaque Psoriasis Therapeutics Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - The...

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that SULINNO (adalimumab injection), a recombinant human anti-TNF- monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of polyarticular juvenile idiopathic arthritis (pJIA), which is the fourth approved indication of SULINNO in China. On September 2, 2020, SULINNO was approved by NMPA for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis.

Juvenile idiopathic arthritis (JIA) is defined as arthritis with an unknown cause lasting at least 6 weeks in children aged 16 years or younger. Arthritis is divided into oligarthritis <5 jointsand polyarthritis. Polyarthritis can be further divided into rheumatoid factor (RF)-negative polyarthritis and RF-positive polyarthritis. It is estimated RF-negative polyarticular JIA affects 1 to 4 per 100,000 children annually. Less commonly, RF-positive polyarticular JIA occurs in an estimated 0.3 to 0.7 per 100,000 children each year. JIA occurs in children at a young age, and is often accompanied by many complications that will lead to high rates of defects, disability and mortality when left untreated, deeply impacting the quality of life in children. Early aggressive therapy leads to improved outcomes and prevents potential disease complications.

Since the launch of adalimumab, it has been approved worldwide for the treatment of seventeen diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriasis arthritis, juvenile idiopathic arthritis, crohn's disease (including pediatric crohn's disease), ulcerative colitis, hidradenitis suppurativa, uveitis, etc. The efficacy and safety of adalimumab has been well recognized globally, and adalimumab injection is widely used in the North America and Europe. It has been consistently recommended in multiple diagnostic and therapeutic guidelines for the treatment of these diseases, and its significant efficacy has been universally recognized. SULINNO is adalimumab biosimilar developed by Innovent, and its clinical results were published in the Inaugural Issue of The Lancet Rheumatology in 2019. The launch of SULINNO has provided more Chinese patients with high-quality and relatively affordable adalimumab injection, bringing hope and opportunities to more patients.

Dr. Qian Lei, Senior Director of Medical Sciences and Strategies of Special Diseases of Innovent, stated: "Not only does Juvenile idiopathic arthritic lead to functional impairment and decrease in quality of life and social participation in children, but also places a huge economic burden on their families. The approval of SULINNO will provide a high-quality and accessible treatment option for children with polyarticular idiopathic arthritis in China. We hope that this product will benefit more children with polyarticular idiopathic arthritis and their families, allowing them to receive early treatment with high-quality biological drugs.''

About SULINNO

SULINNO is an adalimumab (Humira) biosimilar and a recombinant human anti-TNF- monoclonal antibody independently developed by Innovent. TNF is a proinflammatory cytokine mainly produced by activated macrophages, natural killer cells and T lymphocytes, which is involved in inflammatory and immune responses. Anti-TNF- antibody can bind to human TNF- monomer or trimer, block TNF- binding to the cellular surface receptor, p55 and p75, and neutralize the cytotoxic effect of TNF-, thereby inhibiting the release of TNF- mediated inflammatory factors and cytokines, the adhesion and infiltration of inflammatory cells, the proliferation of fibroblasts and the activation of osteoclasts.

The results of a complete pre-clinical comparison showed that SULINNO has similar in vitro biological activity (binding activity to target antigen TNF- and neutralizing activity), physicochemical property and pharmacokinetic characteristics to those of Humira. The similarities were also demonstrated in pharmacological and toxicological studies. The head-to-head clinical study comparing SULINNO and Humira conducted in patients with ankylosing spondylitis demonstrated a clinical similarity. The study results were published at Inaugural Issue of The Lancet Rheumatology in 2019.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar) , SULINNO (adalimumab biosomilar) and HALPRYZA(rituximab biosimilar)on market, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in clinical trials. TYVYT (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China's biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients' lives. For more information, please visit: http://www.innoventbio.com.

View original content:http://www.prnewswire.com/news-releases/innovent-announces-nmpa-granted-new-indication-approval-for-sulinno-adalimumab-injection-in-china-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis-301178781.html

SOURCE Innovent Biologics

Company Codes: HongKong:1801, OTC-PINK:IVBIY

The rest is here:
Innovent Announces NMPA Granted New Indication Approval for SULINNO (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile...

This article was originally published here

Expert Opin Biol Ther. 2020 Nov 20. doi: 10.1080/14712598.2021.1853698. Online ahead of print.

ABSTRACT

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged 18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen cytokine storm of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

PMID:33216643 | DOI:10.1080/14712598.2021.1853698

Read more:
Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID...

EXTON, Pa., Nov. 17, 2020 /PRNewswire/ --The 2020 audit included in Spherix's RealWorld Dynamix: Biologic/Small Molecule Switching in Psoriasis (US) service focuses on a critical facet of overall therapy prescribing for plaque psoriasis (PSO) patients advanced therapy switching. The study captures the myriad of data surrounding the process by which PSO patients are switched from one biologic/small molecule agent to another.

Since the introduction of AbbVie's Skyrizi in April 2019, switch-to share for the IL-23 inhibitor class has nearly tripled. The newest market entrant now garners the greatest switch-to rate among all commercial biologics in PSO and has made great strides in the second- and third-line setting compared to 2019.

Which brands are taking the biggest hit? Two biologics in particular who once held their position as leaders in the market year over year, Novartis' Cosentyx and AbbVie's Humira, have seen consecutive declines in switch-to share since the introduction of Skyrizi.

However, the AbbVie portfolio remains strong, as patients who were switched to Skyrizi often switched from sister brand Humira offsetting any deficits the TNF inhibitor experienced. Of note, the percent of current Skyrizi patients being switched from Amgen's Otezla (a commonly used first-line agent in addition to the TNF inhibitors) has substantially increased from the prior year. This, coupled with the fact that switches from IL-17 inhibitors (which are more commonly used in later lines of therapy) are decreasing, suggests that Skyrizi is being prescribed earlier in the treatment algorithm.

The Spherix study, which assesses reasons behind prescribing behavior, found that efficacy in both skin and joints remains a top reason for current brand selection in PSO, highlighting the importance of treating psoriatic disease. Although IL-17 inhibitors are prescribed more often than IL-23 inhibitors when joint involvement is a factor, the IL-23 class is gaining momentum. In July 2020, Janssen's Tremfya became the first IL-23 inhibitor to gain FDA approval for the treatment of moderate to severe psoriatic arthritic (PsA).

Indeed, nearly one-third of Tremfya patients included in the study present with any joint symptoms, a figure that is not far off from the rates seen in patients being treated with IL-17 inhibitors. The audit also found that considerably more PSO patients overall present with mild joint involvement than moderate to severe indicating the "mild PsA" patient segment in PSO presents a greater opportunity for brands to capture more share.

When examining the switch-to brand based on the severity of joint involvement, the IL-23 inhibitors are being prescribed more often for patients with concomitant mild PsA than moderate to severe and that number has grown since the prior year. On the other hand, slightly less PSO patients with mild joint involvement were switched to an IL-17 inhibitor, and that figure has declined year over year.

As the PSO market is expected to further expand in 2021 with UCB's bimekizumab, a dual IL-17A and IL-17F inhibitor, switching market dynamics are likely to continue shifting. In fact, the majority of PSO patients are considered potential candidates for bimekizumab (pending approval) should their current switch-to agent deem unsuccessful followed by Eli Lilly's pipeline IL-23 inhibitor, mirikizumab.

Patients currently prescribed TNF and IL-17 inhibitors are more likely to be considered for bimekizumab than patients being treated with other mechanisms of action. Interestingly, patients currently on an IL-23 inhibitor are more likely to be considered for mirikizumab, while current Otezla patients are more likely to be considered for other oral agents, such as BMS' TYK2 inhibitor, deucravacitinib highlighting further in-class competition in the PSO switch market.

About RealWorld DynamixRealWorld Dynamix: Biologic/Small Molecule Switching in Psoriasis (US) is an independent, data-driven service unmasking real patient management patterns through annual reports based on chart audits of ~1,000 patients. The report uncovers the "why" behind treatment decisions, includes year over year trending to quantify key aspects of market evolution, and integrates specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Kristen Henn, Business Development ManagerEmail:[emailprotected]www.spherixglobalinsights.com

SOURCE Spherix Global Insights

Spherix Global Insights

Original post:
IL-23 Inhibitors Take Over the US Psoriasis Switching Market at the Expense of the IL-17 and TNF Inhibitors - PRNewswire

Brandi Glanvilleisan open book. From her dating life to friendship quarrels to thecosmetic procedures she's had done, The Real Housewives of Beverly Hills alum has never heldback details on her experiences. Now, she's opening up about a part of her life we've rarely seen.

On November 13, Brandi shared a photo of herself on Instagram, but this wasn't her usual glammed-up selfie. The snap showed a very raw and real look at Brandi's struggle with Psoriasis. Brandi appeared to be going through a flare-up from the skin condition on her face.

"For Friday the 13th Im sharing something scary!" she wrote. "Psoriasis taking over my face & Im depressed about. Thank God for masks."

According to the National Psoriasis Foundation, Psoriasis is an immune-mediated disease that causes raised, scaly patches to appear on the skin. Celebs Kim Kardashian West and LeAnne Rimes, who is married to Brandi's ex-husband, Eddie Cibrian, have also opened up about living with the skin condition.

Want moreRHOBH? Catch up on the latest season through theBravo app.

Bravos Style & Living is your window to the fabulous lifestyles of Bravolebrities. Be the first to know about all the best fashion and beauty looks, the breathtaking homes Bravo stars live in, everything theyre eating and drinking, and so much more. Sign up to become a Bravo Insider and get exclusive extras.

Follow this link:
Brandi Glanville Reveals Her Struggle with Psoriasis: It's "Taking Over My Face" - Bravo

Data indicate that psoriasis is one of the most common immune-mediated disorders, affecting approximately 0.5% to 11.4% of adults worldwide and significantly impacting patients quality of life. Other research suggests that colorectal cancer (CRC) is one of the leading causes of cancer-related mortality and the fourth most commonly diagnosed cancer in both men and women worldwide (900,000 deaths and 1.8 million new cases annually according to the WHO). With psoriasis and CRC both related to immune-mediated chronic inflammation and interleukin-17 shown to be involved in the pathogenesis of psoriasis and initiation of CRC, it has been hypothesized that patients with psoriasis are at increased risk for comorbid CRC. However, the relationship between the two conditions remains unclear.

A Systematic Review & Meta-analysis

To appraise the evidence on the relationship between psoriasis and CRC, Ching-Chi Chi, MD, MMS, DPhil, FAAD, and colleagues conducted a systematic review and meta-analysis of observational studies that examined this association, publishing their results in the Journal of the American Academy of Dermatology. We searched MEDLINE and Embase on March 24, 2020 for relevant studies, explains Dr. Chi. Included studies provided data on the risk for CRC and had a case group of patients with psoriasis and a control group of patients without psoriasis. Nine cohort studies with more than 10.5 million subjects were included.

The Newcastle-Ottawa scale was used to evaluate the risk of bias of included studies, and we conducted random-effects model meta-analysis and subgroup analysis based on gender, notes Dr. Chi. When relevant data were available, the study team conducted meta-analysis on the risk for colon cancer and rectal cancer, as CRC is composed of both. Meta-analyses were only conducted when there were at least three included studies for a given outcome, with the researchers applying the random-effects model due to the expectation of clinical heterogeneity across the included studies.

Significantly Increased Colorectal Cancer Risk

Eight studies that provided data for the meta-analysis demonstrated an increased risk for CRC in patients with psoriasis (Table). We found a significantly increased risk for CRC in patients with psoriasis upon meta-analysis, with patients with psoriasis having a 16% greater risk for CRC than the general population, says Dr. Chi. Subgroup analysis for rectal and colon cancer provided similar results. Five studies providing data on risk for colon cancer found significantly increased risks among patients with psoriasis when compared with controls (HR, 1.14; 95% CI, 1.05-1.24). Three studies reporting data on rectal cancer risk found an increased, but not significantly increased, risk among patients with psoriasis when compared with controls (HR, 1.18; 95% CI, 0.99-1.41). No statistical heterogeneity was seen across the eight, five, or three studies in each of these meta-analyses.

Subgroups analysis based on gender found significantly increased risk for CRC in female patients with psoriasis across five included studies (HR, 1.41; 95% CI, 1.16-1.72) but not in male patients with psoriasis across five included studies (HR, 1.18; 95% CI, 0.92-1.50), notes Dr. Chi.

Looking Ahead

While the cohort studies in the meta-analysis and other reviews indicate that patients with psoriasis have an increased risk for colorectal cancer, the pathogenesis between psoriasis and CRC remains ambiguous, says Dr. Chi. More studies are warranted to confirm if psoriasis and CRC share genetic susceptibility, molecular defect and microbiota imbalance. In the meantimewith patients with early stage colorectal cancer initially exhibiting no symptoms, the possible fatal risk of late-stage colorectal cancer, and evidence that early CRC diagnosis improves survivalhe suggests that gastroenterology consultation and detailed colonoscopy examination are indicated for patients with psoriasis who present with bowel symptoms.

Association of Psoriasis with Colorectal Cancer: A Systematic Review and Meta-Analysishttps://www.jaad.org/article/S0190-9622(20)32643-8/fulltext

Here is the original post:
Exploring the Link Between Psoriasis & Colorectal Cancer - Physician's Weekly

On 17 November 2020, Novartis registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnsons Stelara (ustekinumab). The 28-week study is expected to be completed in 310 subjects who have failed treatment with a tumor necrosis factor (TNF) inhibitor, and the studys primary endpoint is the Health Assessment Questionnaire-Disability Index (HAQ-DI). With the plethora of biologic therapies available, post-marketing head-to-head clinical trials are a critical method through which prescribers can compare drugs directly against one another. The registration of this trial demonstrates Novartis continued efforts to solidify its position in an increasingly crowded market.

Although Novartis has committed significant resources towards marketing Cosentyx, the last few years have brought bad news to the brand from head-to-head comparator trials in the rheumatology space. This latest trial in PsA comes one year after the news that Cosentyx failed to demonstrate statistically significant improvement compared with AbbVies TNF-inhibitor Humira (adalimumab) in the Phase III EXCEED Trial (NCT02745080), sponsored by Novartis themselves. The company had hoped Cosentyx would demonstrate statistically significant superiority measures in terms of its primary endpoint, the American College of Rheumatology score of 20% improvement (ACR20), a measure that would have made them serious contenders for first-line therapies especially given the 2019 EULAR guideline revisions. The change in the primary endpoint is likely a reflection of Novartis desire to avoid a repeat performance in this trial, focusing on a quality of life measure instead of clinical improvement.

After the TNF-inhibitors, J&Js Stelara is a PsA market leader and incredibly popular with dermatologists, who work closely with PsA patients and their rheumatologists to manage both aspects of their disease. Cosentyx, which was approved in PsA in 2015, was a fast rising star in the PsA disease space for several years. However, success in this latest trial is critical to ensure its future in the field. Although Cosentyx had an advantage by being first-in-class, Eli Lillys Taltz is right on its heels with several positive head-to-head results in tow.

Latest report from Visit GlobalData Store

AI Drug Discovery and Development Company

SaaS Platform Decentralizing Clinical Research at Scale

AI Drug Discovery and Development Company

28 Aug 2020

Read more:
Registration of head-to-head psoriatic arthritis clinical trial begins the battle for second place - Clinical Trials Arena

18 November 2020, 13:58 | Updated: 18 November 2020, 16:23

The former Oasis frontman has revealed he's taken to wearing protection on his hands as he describes his skin condition as "raging".

Liam Gallagher has resorted to wearing gloves around the house after a flare up of psoriasis.

The former Oasis frontman has previously revealed he has the skin condition, but this week took to Twitter to let his followers know it was "raging".

Asked by a fan what he was up to today, the Supersonic singer replied: "Cleaning the house my psoriasis is raging so wearing gloves all day".

Fans were quick to share their sympathies and remedies with the Manchester rocker, as others revealed they also suffer with the same condition, which can flare up in winter.

It's not the first time Gallagher has talked about the psoriasis, previously recalling a funny story involving a festival-goer at the band's first Glastonbury appearance who mistook the flakes on his shoulders for cocaine.

"I remember coming off stage and I got my clothes robbed," he told Noisey back in 2017. "I [also] remember meeting someone, some very strange kid, who come up to me and thought I had cocaine in my hair."

He explained: "I got psoriasis [skin condition that causes itchy, scaly rashes] so I had obviously been scratching it during the day and that, and there were little white bits and shit.

"They were takingit out of my hair and putting it on their gums and putting it up their f***ing nose!"

READ MORE: Liam Gallagher announces All You're Dreaming Of single

Meanwhile, Gallagher is preparing to release his festive new single All You're Dreaming Of, which is set fo release on 27 November.

Net proceeds from each download and stream will go to the leading charity, Action For Children, from the day of release until 31st December 2020.

Gallagher said of the track: "All Youre Dreaming Of is an instant classic that is perfect for this time of year. Considering the year that weve all had, I hope this brings back some much needed love and hope. Bing Crosby would have been proud."

READ MORE: Liam Gallagher supports University of Manchester students

Last month also saw Liam announce the details of his Down By The River Thames livestream, which will take place on 5 December.

The show promises to include iconic songs from throughout his career with Oasis as well as his new solo hits and some surprises in between.

The Wall of Glass singer said of the event: "To all my brothers and sisters around the world. I'm performing a one-off celestial live performance for you to stream, 'Down By The River Thames', on 5th December 2020. I'll be performing tracks from my two number 1 solo albums as well as some stone cold Oasis classics, some of which you haven't heard me sing for a long, long time. C'mon you know. LG x".

Stream 1 Saturday 5 December 8pm GMT for UK, Ireland and Europe.

Stream 2 - Saturday 5 December 8pm ET for East Coast North America and South America.

Stream 3 - Saturday 5 December 8pm PT for West Coast North America and Central America.

Stream 4 - Sunday 6 December 8pm AEST for Australia, New Zealand and Asia.

READ MORE: Which Oasis songs did Liam Gallagher write?

Read the rest here:
Liam Gallagher resorts to wearing gloves to cope with psoriasis flare-up in lockdown - Radio X

Psoriasis Treatment Market research report is the new statistical data source added by A2Z Market Research.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Psoriasis Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280493

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO Pharma A/S, Eli Lilly and Company, UCB S.A., Johnson and Johnson Services, Inc., CELGENE CORPORATION, Pfizer Inc.,, AbbVie Inc., Merck and Co., Inc., _x000D_,

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=280493

Regions Covered in the Global Psoriasis Treatment Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Table of Contents

Global Psoriasis Treatment Market Research Report 2020 2026

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=280493

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the article here:
Comprehensive Report on Psoriasis Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Sun Pharmaceutical Industries...